Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
Status:
Recruiting
Trial end date:
2022-10-21
Target enrollment:
Participant gender:
Summary
This study was divided into two parts. The first part was a dose escalation study: a open
label dose escalation design was used to evaluate the safety, tolerance and pharmacokinetic
characteristics of ZSP1603 in IPF patients. The second part was a randomized double-blind
placebo-controlled design was used to preliminatively investigate the efficacy and safety of
ZSP1603 in the treatment of IPF at the target dose.